Phase 4 Haemophilia Trial, Recruiting NCT05849740 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Haemophilia
Back to Haemophilia

Phase 4 Haemophilia Trial, Recruiting

NCT05849740
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Acquired Hemophilia A (AHA), a condition where the body mistakenly attacks a clotting protein in the blood
  • Women who have gone through menopause, or women who could become pregnant but are using reliable contraception throughout the trial
  • People who are able and willing to follow the trial's requirements and attend appointments as needed

Who may not be able to join:

  • People born with hemophilia who have developed antibodies (inhibitors) that block treatment
  • Women who are pregnant or breastfeeding
  • People who test positive for hepatitis B, hepatitis C, HIV, or syphilis
  • People who are unlikely to follow the trial's schedule or requirements
  • People who are unable or unwilling to use contraception during the trial
  • People with Acquired von Willebrand disease, a separate blood clotting condition
  • People who, in the trial doctor's judgment, should not participate for any other medical reason
  • People who received immune-suppressing treatment in the four weeks before joining, where the inhibitor levels were already steadily decreasing by less than half (confirm with trial site for exact details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Lei Zhang, Chinese Academy of Medical Science and Blood Disease Hospital

Phone: +8613820261971

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
22 May 2023
Est. completion
30 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Total response rate to treatment (OR) Total response rate to treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov